French Health Minister aims to expand OTCs

8 January 2007

French Health Minister Xavier Bertrand has called for a report on the functioning of the self-medication - or over-the-counter drugs - market in France with a view to reversing the current contraction.

Non-prescription medicines account for between 4% and 6% of the total market - 350 million packs a year - or about 1.6 billion euros ($2.11 billion), according to the sector association Afipa. Sales went down 3% last year in contrast to the position in other European countries. The German self-medication segment, for example, accounts for 12% of the total market and is estimated to be worth 5.0 billion euros.

In contrast, French consumption of self-medication products is very low, with patients generally preferring to consult a doctor. Claude Le Pen, a French health economist, says that self-medication represents an economic potential far superior to that of generics and Afipa estimates that transferring 5% of current prescriptions to self-medication would save some 2.5 billion euros a year for the health funds.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight